the aid library

LIST OPTIONS

Filter

6630

Task-shifting to improve asthma education for Malawian children: a qualitative analysis

Nkhalamba, L.; Rylance, S.; Muula, S. A. et al. Human Resources for Health (2021) CC

Background Asthma education, a key component of long-term asthma management, is challenging in resource-limited settings with shortages of clinical staff. Task-shifting educational roles to lay (non-clinical) staff is a potential solution. We conducted a randomised controlled trial of an enhanced a... more

Pediatric Asthma: A Global Epidemic

Serebrisky, D.; Wiznia, A. Annals of Global Health (2019) CC

The global prevalence, morbidity and mortality related to childhood asthma among children has increased significantly over the last 40 years. Although asthma is recognized as the most common chronic disease in children, issues of underdiagnosis and undertreatment persist. There are substantial globa... more

ERS/EAACI statement on adherence to international adult asthma guidelines

Mathioudakis, A.G.; Tsilochristou, O.; Adcock, I. M.; et al. (2021) CC2

In the European Union, over 20 million people suffer from asthma. During the 1990s there was a rapid decrease in asthma mortality, probably related to the increased use of inhaled corticosteroids (ICS). However, during the last decade, asthma mortality rates have plateaued, and a consistently high p... more

World Asthma Day: Nigerian Thoracic Society advocates better asthma care in Nigeria

Aikulola, S. (2023) CC2

As part of efforts to celebrate World Asthma Day (WAD), May 2, 2023, and reduce the burden of asthma in Nigeria, the Nigerian Thoracic Society (NTS) has advocated education of asthma patients and carers as an integral part of asthma care to achieve optimal control of ... and exacerbation. more

External Link (214)

The diagnosis of asthma in children: An evidence-based approach to a common clinical dilemma

Masekala, R.; Risenga, S.M.; Kitchin, O.P. et al. South African Medical Journal (2018) CC

Asthma is a heterogeneous condition characterised by chronic inflammation and variable expiratory airflow limitation, as well as airway reversibility. The diagnosis of asthma in young children is limited by the inability to perform objective lung function testing in this group of patients and the wi... more

What is Asthma? - Global Allergy & Airways

Global Allergy & Airways (2024) CC2

Asthma is a chronic (long-term) lung condition that affects your airways or bronchial tubes. It can cause your airways to narrow and their lining to swell and to produce extra mucus, which makes it more difficult to breathe. The narrowing of the airways causes you to feel short of breath, wheeze, or... more

Silica-associated lung disease: An old-world exposure in modern industries

Barnes, H.; Goh, N. S. L.; Leong, T. L.; Hoy, R. Official Journal of the Asian Pacific Society of Respirology (2019) CC2

Silicosis is not a new disease; the impact of silica dust on respiratory function was observed by Hippocrates in 430 B.C. and in the 16th century by Agricol. In 1713, Rammazini described silicotic nodules in post-mortems of stone cutters presenting with respiratory .... In the mid-late 1800s, the introduction of mechanized tools in the mining sector rapidly increased levels of silica exposure, resulting in an increase in cases and our understanding of silicosis. more

Implications of the Marburg virus disease outbreak in Rwanda for the EU/EEA, 2024

European Centre for Disease Prevention and Control (ecdc) (2024) C_CDC

This threat assessment addresses the implications of the ongoing Marburg virus disease (MVD) outbreak in Rwanda for the European Union/European Economic Area (EU/EEA). MVD is a severe disease in humans and, although uncommon, it has the potential to cause epidemics with significant case fatality. ... more

External Link (616)

Marburg virus disease outbreak – Rwanda 2024

World Health Organisation (WHO) (2024) C_WHO

On 27 September 2024, the Ministry of Health of Rwanda confirmed the country’s first outbreak of Marburg virus disease (MVD), with health-care workers in Kigali particularly affected. While sporadic outbreaks have occurred in various parts of Africa since the first recognized cases in 1967, this o... more

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

External Link (483)

Skin NTDs App
recommended

World Health Organisation WHO (2024) C_WHO

Recognizing neglected tropical diseseases through changes on the skin. App for Android and IOS, free of charge. The App is available in English and French, with plans to explore translations into other languages, such as Portuguese and Spanish, to better serve diverse communities. A patient's skin... more

Download (204)

View PDF (208)

Treatment of Malaria (Guidelines for Clinicians)

Centers for Disease Control and Prevention CDC (2019) C_CDC

Because malaria cases are seen relatively rarely in North America, misdiagnosis by clinicians and laboratorians has been a commonly documented problem in published reports. However, malaria may be a common illness in areas where it is transmitted and therefore the diagnosis of malaria should routine... more

Download (219)

View PDF (288)

Target product profile for a rapid test for diagnosis of Buruli ulcer at the primary health-care level

World Health Organization WHO (2022) C_WHO

In 2009, WHO’s Second International Conference on Buruli Ulcer Control and Research resolved to strengthen the capacity of national laboratories to confirm cases of the disease, but advised that “efforts are still needed to develop simple diagnostic tools usable in the field as well as disabilit... more

External Link

Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

Smith, E.E.; Saposnik, G.; Biessels. G.J. et al. American Heart Association (2016) CC

Two decades of epidemiological research shows that silent cerebrovascular disease is common and is associated with future risk for stroke and dementia. It is the most common incidental finding on brain scans. To summarize evidence on the diagnosis and management of silent cerebrovascular disease to ... more

WHO guideline on preventive chemotherapy for public health control of strongyloidiasis
recommended

World Health Organization WHO (2024) C_WHO

Human strongyloidiasis is a chronic parasitic disease caused by infection with Strongyloides stercoralis, a soil-transmitted helminth that is estimated to infect 300–600 million people worldwide. This neglected tropical disease (NTD) is endemic globally, predominately in the South-East Asia, Afric... more

Challenges in the Management of Bronchial Asthma Among Adults in Nigeria: A Systematic Review

Onyedum, C.C.; Ukwaja, K.N.; Desula, O.O.; Ezeudo, D. (2013) CC2

Asthma is a chronic inflammatory condition characterized by airway hyper-responsiveness to a variety of stimuli largely of allergic origin with reversible airflow limitation. The major clinical features of asthma are wheezing, shortness of breath, and cough. It is a major cause of impaired quality o... more

External Link

Effect of COVID-19 pandemic on provision of sexual and reproductive health services in primary health facilities in Nigeria: a cross-sectional study

Adelekan, B.; E. Goldson, Z. Abubakar et al. Repoductive Health Journal (2021) CC

RESULTS: Between 76 and 97% of the PHCS offered RMCAH services before the lockdown. Except in antenatal, delivery and adolescent care, there was a decline of between 2 and 6% in all the services during the lockdown and up to 10% decline after the lockdown with variation across and within States. Dur... more

External Link

Impact of human schistosomiasis in sub-Saharan Africa

Adenowo, A.; Oyinloye, B.; Ogunyinka, B. et al. (2015) CC

Human schistosomiasis otherwise called bilharzia, is a fresh- water snail transmitted intravascular debilitating disease resulting from infection by the parasitic dimorphic Schistosoma trematode worms, which lives in the bloodstream of humans. The World Health Organization (WHO) regards the disease ... more

Download (174)

View PDF (313)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 10 August 2023

World Health Organization WHO (2023) C_WHO

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (290)

View PDF (386)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Skin NTDs App recommended

WHO guideline on preventive chemotherapy for public health control of strongyloidiasis ﻿ recommended

Skin NTDs App
recommended

WHO guideline on preventive chemotherapy for public health control of strongyloidiasis
recommended